From HandWiki
Short description: Primary male sex hormone
The chemical structure of testosterone.
A ball-and-stick model of testosterone.
IUPAC name
Preferred IUPAC name
Other names
3D model (JSmol)
EC Number
  • 200-370-5
Molar mass 288.431 g·mol−1
Melting point 151.0 °C (303.8 °F; 424.1 K)
1=ATC code }} G03BA03 (WHO)
License data
Transdermal (gel, cream, solution, patch), by mouth (as testosterone undecanoate), in the cheek, intranasal (gel), intramuscular injection (as esters), subcutaneous pellets
Oral: very low (due to extensive first pass metabolism)
97.0–99.5% (to SHBG and albumin)[1]
Liver (mainly reduction and conjugation)
30–45 minutes
Urine (90%), feces (6%)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☑Y verify (what is ☑Y☒N ?)
Infobox references
Tracking categories (test):

Testosterone is the primary sex hormone and anabolic steroid in males.[2] In humans, testosterone plays a key role in the development of male reproductive tissues such as testes and prostate, as well as promoting secondary sexual characteristics such as increased muscle and bone mass, and the growth of body hair.[3] In addition, testosterone in both sexes is involved in health and well-being, including moods, behaviour, and in the prevention of osteoporosis.[4][5] Insufficient levels of testosterone in men may lead to abnormalities including frailty and bone loss.

Testosterone is a steroid from the androstane class containing a ketone and a hydroxyl group at positions three and seventeen respectively. It is biosynthesized in several steps from cholesterol and is converted in the liver to inactive metabolites.[6] It exerts its action through binding to and activation of the androgen receptor.[6] In humans and most other vertebrates, testosterone is secreted primarily by the testicles of males and, to a lesser extent, the ovaries of females. On average, in adult males, levels of testosterone are about seven to eight times as great as in adult females.[7] As the metabolism of testosterone in males is more pronounced, the daily production is about 20 times greater in men.[8][9] Females are also more sensitive to the hormone.[10]

In addition to its role as a natural hormone, testosterone is used as a medication in the treatment of hypogonadism in men and breast cancer in women.[11] Since testosterone levels decrease as men age, testosterone is sometimes used in older men to counteract this deficiency. It is also used illicitly to enhance physique and performance, for instance in athletes.[12] The World Anti-Doping Agency is listing it as S1 Anabolic agent substance "prohibited at all times".[13]

Biological effects

In general, androgens such as testosterone promote protein synthesis and thus growth of tissues with androgen receptors.[14] Recently, Gharahdaghi reported that endogenous and exogenous testosterone play a permissive role in adaptation to exercise training in younger and older men.[15][16][17]Testosterone can be described as having virilising and anabolic effects (though these categorical descriptions are somewhat arbitrary, as there is a great deal of mutual overlap between them).[18]

  • Anabolic effects include growth of muscle mass and strength, increased bone density and strength, and stimulation of linear growth and bone maturation.
  • Androgenic effects include maturation of the sex organs, particularly the penis, and the formation of the scrotum in the fetus, and after birth (usually at puberty) a deepening of the voice, growth of facial hair (such as the beard) and axillary (underarm) hair. Many of these fall into the category of male secondary sex characteristics.

Testosterone effects can also be classified by the age of usual occurrence. For postnatal effects in both males and females, these are mostly dependent on the levels and duration of circulating free testosterone.[19]

Before birth

Effects before birth are divided into two categories, classified in relation to the stages of development.

The first period occurs between 4 and 6 weeks of the gestation. Examples include genital virilisation such as midline fusion, phallic urethra, scrotal thinning and rugation, and phallic enlargement; although the role of testosterone is far smaller than that of dihydrotestosterone. There is also development of the prostate gland and seminal vesicles.

During the second trimester, androgen level is associated with sex formation.[20] Specifically, testosterone, along with anti-Müllerian hormone (AMH) promote growth of the Wolffian duct and degeneration of the Müllerian duct respectively.[21] This period affects the femininization or masculinization of the fetus and can be a better predictor of feminine or masculine behaviours such as sex typed behaviour than an adult's own levels. Prenatal androgens apparently influence interests and engagement in gendered activities and have moderate effects on spatial abilities.[22] Among women with congenital adrenal hyperplasia, a male-typical play in childhood correlated with reduced satisfaction with the female gender and reduced heterosexual interest in adulthood.[23]

Early infancy

Early infancy androgen effects are the least understood. In the first weeks of life for male infants, testosterone levels rise. The levels remain in a pubertal range for a few months, but usually reach the barely detectable levels of childhood by 4–7 months of age.[24][25] The function of this rise in humans is unknown. It has been theorized that brain masculinization is occurring since no significant changes have been identified in other parts of the body.[26] The male brain is masculinized by the aromatization of testosterone into estrogen, which crosses the blood–brain barrier and enters the male brain, whereas female fetuses have α-fetoprotein, which binds the estrogen so that female brains are not affected.[27]

Before puberty

Before puberty, effects of rising androgen levels occur in both boys and girls. These include adult-type body odor, increased oiliness of skin and hair, acne, pubarche (appearance of pubic hair), axillary hair (armpit hair), growth spurt, accelerated bone maturation, and facial hair.[28]


Pubertal effects begin to occur when androgen has been higher than normal adult female levels for months or years. In males, these are usual late pubertal effects, and occur in women after prolonged periods of heightened levels of free testosterone in the blood. The effects include:[28][29]

  • Growth of spermatogenic tissue in testicles, male fertility, penis or clitoris enlargement, increased libido and frequency of erection or clitoral engorgement occurs.
  • Growth of jaw, brow, chin, and nose and remodeling of facial bone contours, in conjunction with human growth hormone occurs.[30]
  • Completion of bone maturation and termination of growth. This occurs indirectly via estradiol metabolites and hence more gradually in men than women.
  • Increased muscle strength and mass, shoulders become broader and rib cage expands, deepening of voice, growth of the Adam's apple.
  • Enlargement of sebaceous glands. This might cause acne, subcutaneous fat in face decreases.
  • Pubic hair extends to thighs and up toward umbilicus, development of facial hair (sideburns, beard, moustache), loss of scalp hair (androgenetic alopecia), increase in chest hair, periareolar hair, perianal hair, leg hair, armpit hair.


Testosterone is necessary for normal sperm development. It activates genes in Sertoli cells, which promote differentiation of spermatogonia. It regulates acute HPA (hypothalamic–pituitary–adrenal axis) response under dominance challenge.[31] Androgens including testosterone enhance muscle growth. Testosterone also regulates the population of thromboxane A2 receptors on megakaryocytes and platelets and hence platelet aggregation in humans.[32][33]

Adult testosterone effects are more clearly demonstrable in males than in females, but are likely important to both sexes. Some of these effects may decline as testosterone levels might decrease in the later decades of adult life.[34]

Health risks

Testosterone does not appear to increase the risk of developing prostate cancer. In people who have undergone testosterone deprivation therapy, testosterone increases beyond the castrate level have been shown to increase the rate of spread of an existing prostate cancer.[35][36][37]

Conflicting results have been obtained concerning the importance of testosterone in maintaining cardiovascular health.[38][39] Nevertheless, maintaining normal testosterone levels in elderly men has been shown to improve many parameters that are thought to reduce cardiovascular disease risk, such as increased lean body mass, decreased visceral fat mass, decreased total cholesterol, and glycemic control.[40]

High androgen levels are associated with menstrual cycle irregularities in both clinical populations and healthy women.[41]

Sexual arousal

Testosterone levels follow a nycthemeral rhythm that peaks early each day, regardless of sexual activity.[42]

There are positive correlations between positive orgasm experience in women and testosterone levels where relaxation was a key perception of the experience. There is no correlation between testosterone and men's perceptions of their orgasm experience, and also no correlation between higher testosterone levels and greater sexual assertiveness in either sex.[43]

Sexual arousal and masturbation in women produce small increases in testosterone concentrations.[44] The plasma levels of various steroids significantly increase after masturbation in men and the testosterone levels correlate to those levels.[45]

Mammalian studies

Studies conducted in rats have indicated that their degree of sexual arousal is sensitive to reductions in testosterone. When testosterone-deprived rats were given medium levels of testosterone, their sexual behaviours (copulation, partner preference, etc.) resumed, but not when given low amounts of the same hormone. Therefore, these mammals may provide a model for studying clinical populations among humans with sexual arousal deficits such as hypoactive sexual desire disorder.[46]

Every mammalian species examined demonstrated a marked increase in a male's testosterone level upon encountering a novel female. The reflexive testosterone increases in male mice is related to the male's initial level of sexual arousal.[47]

In non-human primates, it may be that testosterone in puberty stimulates sexual arousal, which allows the primate to increasingly seek out sexual experiences with females and thus creates a sexual preference for females.[48] Some research has also indicated that if testosterone is eliminated in an adult male human or other adult male primate's system, its sexual motivation decreases, but there is no corresponding decrease in ability to engage in sexual activity (mounting, ejaculating, etc.).[48]

In accordance with sperm competition theory, testosterone levels are shown to increase as a response to previously neutral stimuli when conditioned to become sexual in male rats.[49] This reaction engages penile reflexes (such as erection and ejaculation) that aid in sperm competition when more than one male is present in mating encounters, allowing for more production of successful sperm and a higher chance of reproduction.


In men, higher levels of testosterone are associated with periods of sexual activity.[50][51]

Men who watch a sexually explicit movie have an average increase of 35% in testosterone, peaking at 60–90 minutes after the end of the film, but no increase is seen in men who watch sexually neutral films.[52] Men who watch sexually explicit films also report increased motivation, competitiveness, and decreased exhaustion.[53] A link has also been found between relaxation following sexual arousal and testosterone levels.[54]

Men's levels of testosterone change depending on whether they are exposed to an ovulating or nonovulating woman's body odour. Men who are exposed to scents of ovulating women maintained a stable testosterone level that was higher than the testosterone level of men exposed to nonovulation cues. Men are heavily aware of hormone cycles in women.[55] This may be linked to the ovulatory shift hypothesis,[56] where males are adapted to respond to the ovulation cycles of females by sensing when they are most fertile and whereby females look for preferred male mates when they are the most fertile; both actions may be driven by hormones.


Androgens may modulate the physiology of vaginal tissue and contribute to female genital sexual arousal.[57] Women's level of testosterone is higher when measured pre-intercourse vs. pre-cuddling, as well as post-intercourse vs. post-cuddling.[58] There is a time lag effect when testosterone is administered, on genital arousal in women. In addition, a continuous increase in vaginal sexual arousal may result in higher genital sensations and sexual appetitive behaviors.[59]

When females have a higher baseline level of testosterone, they have higher increases in sexual arousal levels but smaller increases in testosterone, indicating a ceiling effect on testosterone levels in females. Sexual thoughts also change the level of testosterone but not the level of cortisol in the female body, and hormonal contraceptives may affect the variation in testosterone response to sexual thoughts.[60]

Testosterone may prove to be an effective treatment in female sexual arousal disorders,[61] and is available as a dermal patch. There is no FDA-approved androgen preparation for the treatment of androgen insufficiency; however, it has been used as an off-label use to treat low libido and sexual dysfunction in older women. Testosterone may be a treatment for postmenopausal women as long as they are effectively estrogenized.[61]

Romantic relationships

Falling in love has been linked with decreases in men's testosterone levels while mixed changes are reported for women's testosterone levels.[62] [63] There has been speculation that these changes in testosterone result in the temporary reduction of differences in behavior between the sexes.[63] However, the testosterone changes observed do not seem to be maintained as relationships develop over time.[62][63]

Men who produce less testosterone are more likely to be in a relationship[64] or married,[65] and men who produce more testosterone are more likely to divorce.[65] Marriage or commitment could cause a decrease in testosterone levels.[66] Single men who have not had relationship experience have lower testosterone levels than single men with experience. It is suggested that these single men with prior experience are in a more competitive state than their non-experienced counterparts.[67] Married men who engage in bond-maintenance activities such as spending the day with their spouse and/or child have no different testosterone levels compared to times when they do not engage in such activities. Collectively, these results suggest that the presence of competitive activities rather than bond-maintenance activities are more relevant to changes in testosterone levels.[68]

Men who produce more testosterone are more likely to engage in extramarital sex.[65] Testosterone levels do not rely on physical presence of a partner; testosterone levels of men engaging in same-city and long-distance relationships are similar.[64] Physical presence may be required for women who are in relationships for the testosterone–partner interaction, where same-city partnered women have lower testosterone levels than long-distance partnered women.[69]


Fatherhood decreases testosterone levels in men, suggesting that the emotions and behaviour tied to decreased testosterone promote paternal care. In humans and other species that utilize allomaternal care, paternal investment in offspring is beneficial to said offspring's survival because it allows the two parents to raise multiple children simultaneously. This increases the reproductive fitness of the parents because their offspring are more likely to survive and reproduce. Paternal care increases offspring survival due to increased access to higher quality food and reduced physical and immunological threats.[70] This is particularly beneficial for humans since offspring are dependent on parents for extended periods of time and mothers have relatively short inter-birth intervals.[71]

While the extent of paternal care varies between cultures, higher investment in direct child care has been seen to be correlated with lower average testosterone levels as well as temporary fluctuations.[72] For instance, fluctuation in testosterone levels when a child is in distress has been found to be indicative of fathering styles. If a father's testosterone levels decrease in response to hearing their baby cry, it is an indication of empathizing with the baby. This is associated with increased nurturing behavior and better outcomes for the infant.[73]


Testosterone levels play a major role in risk-taking during financial decisions.[74][75]

Aggression and criminality

Most studies support a link between adult criminality and testosterone. Nearly all studies of juvenile delinquency and testosterone are not significant. Most studies have also found testosterone to be associated with behaviors or personality traits linked with criminality such as antisocial behavior and alcoholism. Many studies have also been done on the relationship between more general aggressive behavior and feelings and testosterone. About half the studies have found a relationship and about half no relationship.[76] Studies have also found that testosterone facilitates aggression by modulating vasopressin receptors in the hypothalamus.[77]

There are two theories on the role of testosterone in aggression and competition.[78] The first one is the challenge hypothesis which states that testosterone would increase during puberty, thus facilitating reproductive and competitive behavior which would include aggression.[78] It is therefore the challenge of competition among males of the species that facilitates aggression and violence.[78] Studies conducted have found direct correlation between testosterone and dominance, especially among the most violent criminals in prison who had the highest testosterone levels.[78] The same research also found fathers (those outside competitive environments) had the lowest testosterone levels compared to other males.[78]

The second theory is similar and is known as "evolutionary neuroandrogenic (ENA) theory of male aggression".[79][80] Testosterone and other androgens have evolved to masculinize a brain in order to be competitive even to the point of risking harm to the person and others. By doing so, individuals with masculinized brains as a result of pre-natal and adult life testosterone and androgens enhance their resource acquiring abilities in order to survive, attract and copulate with mates as much as possible.[79] The masculinization of the brain is not just mediated by testosterone levels at the adult stage, but also testosterone exposure in the womb as a fetus. Higher pre-natal testosterone indicated by a low digit ratio as well as adult testosterone levels increased risk of fouls or aggression among male players in a soccer game.[81] Studies have also found higher pre-natal testosterone or lower digit ratio to be correlated with higher aggression in males.[82][83][84][85][86]

The rise in testosterone levels during competition predicted aggression in males but not in females.[87] Subjects who interacted with hand guns and an experimental game showed rise in testosterone and aggression.[88] Natural selection might have evolved males to be more sensitive to competitive and status challenge situations and that the interacting roles of testosterone are the essential ingredient for aggressive behaviour in these situations.[89] Testosterone mediates attraction to cruel and violent cues in men by promoting extended viewing of violent stimuli.[90] Testosterone-specific structural brain characteristic can predict aggressive behaviour in individuals.[91]

Testosterone might encourage fair behavior. For one study, subjects took part in a behavioral experiment where the distribution of a real amount of money was decided. The rules allowed both fair and unfair offers. The negotiating partner could subsequently accept or decline the offer. The fairer the offer, the less probable a refusal by the negotiating partner. If no agreement was reached, neither party earned anything. Test subjects with an artificially enhanced testosterone level generally made better, fairer offers than those who received placebos, thus reducing the risk of a rejection of their offer to a minimum. Two later studies have empirically confirmed these results.[92][93][94] However men with high testosterone were significantly 27% less generous in an ultimatum game.[95] The Annual NY Academy of Sciences has also found anabolic steroid use (which increases testosterone) to be higher in teenagers, and this was associated with increased violence.[96] Studies have also found administered testosterone to increase verbal aggression and anger in some participants.[97]

A few studies indicate that the testosterone derivative estradiol (one form of estrogen) might play an important role in male aggression.[76][98][99][100] Estradiol is known to correlate with aggression in male mice.[101] Moreover, the conversion of testosterone to estradiol regulates male aggression in sparrows during breeding season.[102] Rats who were given anabolic steroids that increase testosterone were also more physically aggressive to provocation as a result of "threat sensitivity".[103]

The relationship between testosterone and aggression may also function indirectly, as it has been proposed that testosterone does not amplify tendencies towards aggression but rather amplifies whatever tendencies will allow an individual to maintain social status when challenged. In most animals, aggression is the means of maintaining social status. However, humans have multiple ways of obtaining social status. This could explain why some studies find a link between testosterone and pro-social behaviour if pro-social behaviour is rewarded with social status. Thus the link between testosterone and aggression and violence is due to these being rewarded with social status.[104] The relationship may also be one of a "permissive effect" whereby testosterone does elevate aggression levels but only in the sense of allowing average aggression levels to be maintained; chemically or physically castrating the individual will reduce aggression levels (though it will not eliminate them) but the individual only needs a small-level of pre-castration testosterone to have aggression levels to return to normal, which they will remain at even if additional testosterone is added. Testosterone may also simply exaggerate or amplify existing aggression; for example, chimpanzees who receive testosterone increases become more aggressive to chimps lower than them in the social hierarchy but will still be submissive to chimps higher than them. Testosterone thus does not make the chimpanzee indiscriminately aggressive but instead amplifies his pre-existing aggression towards lower-ranked chimps.[105]

In humans, testosterone appears more to promote status-seeking and social dominance than simply increasing physical aggression. When controlling for the effects of belief in having received testosterone, women who have received testosterone make fairer offers than women who have not received testosterone.[106]


The brain is also affected by this sexual differentiation;[20] the enzyme aromatase converts testosterone into estradiol that is responsible for masculinization of the brain in male mice. In humans, masculinization of the fetal brain appears, by observation of gender preference in patients with congenital diseases of androgen formation or androgen receptor function, to be associated with functional androgen receptors.[107]

There are some differences between a male and female brain (possibly the result of different testosterone levels), one of them being size: the male human brain is, on average, larger.[108] Men were found to have a total myelinated fiber length of 176 000 km at the age of 20, whereas in women the total length was 149 000 km (approx. 15% less).[109]

No immediate short term effects on mood or behavior were found from the administration of supraphysiologic doses of testosterone for 10 weeks on 43 healthy men.[110] A correlation between testosterone and risk tolerance in career choice exists among women.[74][111]

Attention, memory, and spatial ability are key cognitive functions affected by testosterone in humans. Preliminary evidence suggests that low testosterone levels may be a risk factor for cognitive decline and possibly for dementia of the Alzheimer's type,[112][113][114][115] a key argument in life extension medicine for the use of testosterone in anti-aging therapies. Much of the literature, however, suggests a curvilinear or even quadratic relationship between spatial performance and circulating testosterone,[116] where both hypo- and hypersecretion (deficient- and excessive-secretion) of circulating androgens have negative effects on cognition.

Immune system and inflammation

Testosterone deficiency is associated with an increased risk of metabolic syndrome, cardiovascular disease and mortality, which are also sequelae of chronic inflammation.[117] Testosterone plasma concentration inversely correlates to multiple biomarkers of inflammation including CRP, interleukin 1 beta, interleukin 6, TNF alpha and endotoxin concentration, as well as leukocyte count.[117] As demonstrated by a meta-analysis, substitution therapy with testosterone results in a significant reduction of inflammatory markers.[117] These effects are mediated by different mechanisms with synergistic action.[117] In androgen-deficient men with concomitant autoimmune thyroiditis, substitution therapy with testosterone leads to a decrease in thyroid autoantibody titres and an increase in thyroid's secretory capacity (SPINA-GT).[118]

Medical use

Main page: Chemistry:Testosterone (medication)

Testosterone is used as a medication for the treatment of male hypogonadism, gender dysphoria, and certain types of breast cancer.[11][119] This is known as hormone replacement therapy (HRT) or testosterone replacement therapy (TRT), which maintains serum testosterone levels in the normal range. Decline of testosterone production with age has led to interest in androgen replacement therapy.[120] It is unclear if the use of testosterone for low levels due to aging is beneficial or harmful.[121]

Testosterone is included in the World Health Organization's list of essential medicines, which are the most important medications needed in a basic health system.[122] It is available as a generic medication.[11] It can be administered as a cream or transdermal patch that is applied to the skin, by injection into a muscle, as a tablet that is placed in the cheek, or by ingestion.[11]

Common side effects from testosterone medication include acne, swelling, and breast enlargement in males.[11] Serious side effects may include liver toxicity, heart disease, and behavioral changes.[11] Women and children who are exposed may develop virilization.[11] It is recommended that individuals with prostate cancer not use the medication.[11] It can cause harm if used during pregnancy or breastfeeding.[11]

2020 guidelines from the American College of Physicians support the discussion of testosterone treatment in adult men with age-related low levels of testosterone who have sexual dysfunction. They recommend yearly evaluation regarding possible improvement and, if none, to discontinue testosterone; physicians should consider intramuscular treatments, rather than transdermal treatments, due to costs and since the effectiveness and harm of either method is similar. Testosterone treatment for reasons other than possible improvement of sexual dysfunction may not be recommended.[123][124]

Biological activity

Free testosterone

Lipophilic hormones (soluble in lipids but not in water), such as steroid hormones, including testosterone, are transported in water-based blood plasma through specific and non-specific proteins. Specific proteins include sex hormone-binding globulin (SHBG), which binds testosterone, dihydrotestosterone, estradiol, and other sex steroids. Non-specific binding proteins include albumin and lipoprotein. The part of the total hormone concentration that is not bound to its respective specific carrier protein is the free part. As a result, testosterone which is not bound to SHBG is called free testosterone. It seems that only the free amount of testosterone can bind to an androgenic receptor, which means they have biological activity.[125]

Steroid hormone activity

The effects of testosterone in humans and other vertebrates occur by way of multiple mechanisms: by activation of the androgen receptor (directly or as dihydrotestosterone), and by conversion to estradiol and activation of certain estrogen receptors.[126][127] Androgens such as testosterone have also been found to bind to and activate membrane androgen receptors.[128][129][130]

Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than testosterone, so that its androgenic potency is about 5 times that of T.[131] The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.

Androgen receptors occur in many different vertebrate body system tissues, and both males and females respond similarly to similar levels. Greatly differing amounts of testosterone prenatally, at puberty, and throughout life account for a share of biological differences between males and females.

The bones and the brain are two important tissues in humans where the primary effect of testosterone is by way of aromatization to estradiol. In the bones, estradiol accelerates ossification of cartilage into bone, leading to closure of the epiphyses and conclusion of growth. In the central nervous system, testosterone is aromatized to estradiol. Estradiol rather than testosterone serves as the most important feedback signal to the hypothalamus (especially affecting LH secretion).[132] In many mammals, prenatal or perinatal "masculinization" of the sexually dimorphic areas of the brain by estradiol derived from testosterone programs later male sexual behavior.[133]

Neurosteroid activity

Testosterone, via its active metabolite 3α-androstanediol, is a potent positive allosteric modulator of the GABAA receptor.[134]

Testosterone has been found to act as an antagonist of the TrkA and p75NTR, receptors for the neurotrophin nerve growth factor (NGF), with high affinity (around 5 nM).[135][136][137] In contrast to testosterone, DHEA and DHEA sulfate have been found to act as high-affinity agonists of these receptors.[135][136][137]

Testosterone is an antagonist of the sigma-1 receptor (Ki = 1,014 or 201 nM).[138] However, the concentrations of testosterone required for binding the receptor are far above even total circulating concentrations of testosterone in adult males (which range between 10 and 35 nM).[139]


Human steroidogenesis, showing testosterone near bottom[140]


Like other steroid hormones, testosterone is derived from cholesterol (see figure).[141] The first step in the biosynthesis involves the oxidative cleavage of the side-chain of cholesterol by cholesterol side-chain cleavage enzyme (P450scc, CYP11A1), a mitochondrial cytochrome P450 oxidase with the loss of six carbon atoms to give pregnenolone. In the next step, two additional carbon atoms are removed by the CYP17A1 (17α-hydroxylase/17,20-lyase) enzyme in the endoplasmic reticulum to yield a variety of C19 steroids.[142] In addition, the 3β-hydroxyl group is oxidized by 3β-hydroxysteroid dehydrogenase to produce androstenedione. In the final and rate limiting step, the C17 keto group androstenedione is reduced by 17β-hydroxysteroid dehydrogenase to yield testosterone.

The largest amounts of testosterone (>95%) are produced by the testes in men,[3] while the adrenal glands account for most of the remainder. Testosterone is also synthesized in far smaller total quantities in women by the adrenal glands, thecal cells of the ovaries, and, during pregnancy, by the placenta.[143] In the testes, testosterone is produced by the Leydig cells.[144] The male generative glands also contain Sertoli cells, which require testosterone for spermatogenesis. Like most hormones, testosterone is supplied to target tissues in the blood where much of it is transported bound to a specific plasma protein, sex hormone-binding globulin (SHBG).


Hypothalamic–pituitary–testicular axis

In males, testosterone is synthesized primarily in Leydig cells. The number of Leydig cells in turn is regulated by luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In addition, the amount of testosterone produced by existing Leydig cells is under the control of LH, which regulates the expression of 17β-hydroxysteroid dehydrogenase.[145]

The amount of testosterone synthesized is regulated by the hypothalamic–pituitary–testicular axis (see figure to the right).[146] When testosterone levels are low, gonadotropin-releasing hormone (GnRH) is released by the hypothalamus, which in turn stimulates the pituitary gland to release FSH and LH. These latter two hormones stimulate the testis to synthesize testosterone. Finally, increasing levels of testosterone through a negative feedback loop act on the hypothalamus and pituitary to inhibit the release of GnRH and FSH/LH, respectively.

Factors affecting testosterone levels may include:

  • Age: Testosterone levels gradually reduce as men age.[147][148] This effect is sometimes referred to as andropause or late-onset hypogonadism.[149]
  • Exercise: Resistance training increases testosterone levels acutely,[150] however, in older men, that increase can be avoided by protein ingestion.[151] Endurance training in men may lead to lower testosterone levels.[152]
  • Nutrients: Vitamin A deficiency may lead to sub-optimal plasma testosterone levels.[153] The secosteroid vitamin D in levels of 400–1000 IU/d (10–25 µg/d) raises testosterone levels.[154] Zinc deficiency lowers testosterone levels[155] but over-supplementation has no effect on serum testosterone.[156] There is limited evidence that low-fat diets may reduce total and free testosterone levels in men,[157] and moderate evidence that short-term, very high protein diets (≥35% protein) decrease total testosterone levels in men.[158]
  • Weight loss: Reduction in weight may result in an increase in testosterone levels. Fat cells synthesize the enzyme aromatase, which converts testosterone, the male sex hormone, into estradiol, the female sex hormone.[159] However no clear association between body mass index and testosterone levels has been found.[160]
  • Miscellaneous: Sleep: (REM sleep) increases nocturnal testosterone levels.[161] Behavior: Dominance challenges can, in some cases, stimulate increased testosterone release in men.[162] Drugs: Natural or man-made antiandrogens including spearmint tea reduce testosterone levels.[163][164][165] Licorice can decrease the production of testosterone and this effect is greater in females.[166]


The plasma protein binding of testosterone is 98.0 to 98.5%, with 1.5 to 2.0% free or unbound.[167] It is bound 65% to sex hormone-binding globulin (SHBG) and 33% bound weakly to albumin.[168]


Both testosterone and 5α-DHT are metabolized mainly in the liver.[1][169] Approximately 50% of testosterone is metabolized via conjugation into testosterone glucuronide and to a lesser extent testosterone sulfate by glucuronosyltransferases and sulfotransferases, respectively.[1] An additional 40% of testosterone is metabolized in equal proportions into the 17-ketosteroids androsterone and etiocholanolone via the combined actions of 5α- and 5β-reductases, 3α-hydroxysteroid dehydrogenase, and 17β-HSD, in that order.[1][169][170] Androsterone and etiocholanolone are then glucuronidated and to a lesser extent sulfated similarly to testosterone.[1][169] The conjugates of testosterone and its hepatic metabolites are released from the liver into circulation and excreted in the urine and bile.[1][169][170] Only a small fraction (2%) of testosterone is excreted unchanged in the urine.[169]

In the hepatic 17-ketosteroid pathway of testosterone metabolism, testosterone is converted in the liver by 5α-reductase and 5β-reductase into 5α-DHT and the inactive 5β-DHT, respectively.[1][169] Then, 5α-DHT and 5β-DHT are converted by 3α-HSD into 3α-androstanediol and 3α-etiocholanediol, respectively.[1][169] Subsequently, 3α-androstanediol and 3α-etiocholanediol are converted by 17β-HSD into androsterone and etiocholanolone, which is followed by their conjugation and excretion.[1][169] 3β-Androstanediol and 3β-etiocholanediol can also be formed in this pathway when 5α-DHT and 5β-DHT are acted upon by 3β-HSD instead of 3α-HSD, respectively, and they can then be transformed into epiandrosterone and epietiocholanolone, respectively.[171][172] A small portion of approximately 3% of testosterone is reversibly converted in the liver into androstenedione by 17β-HSD.[170]

In addition to conjugation and the 17-ketosteroid pathway, testosterone can also be hydroxylated and oxidized in the liver by cytochrome P450 enzymes, including CYP3A4, CYP3A5, CYP2C9, CYP2C19, and CYP2D6.[173] 6β-Hydroxylation and to a lesser extent 16β-hydroxylation are the major transformations.[173] The 6β-hydroxylation of testosterone is catalyzed mainly by CYP3A4 and to a lesser extent CYP3A5 and is responsible for 75 to 80% of cytochrome P450-mediated testosterone metabolism.[173] In addition to 6β- and 16β-hydroxytestosterone, 1β-, 2α/β-, 11β-, and 15β-hydroxytestosterone are also formed as minor metabolites.[173][174] Certain cytochrome P450 enzymes such as CYP2C9 and CYP2C19 can also oxidize testosterone at the C17 position to form androstenedione.[173]

Two of the immediate metabolites of testosterone, 5α-DHT and estradiol, are biologically important and can be formed both in the liver and in extrahepatic tissues.[169] Approximately 5 to 7% of testosterone is converted by 5α-reductase into 5α-DHT, with circulating levels of 5α-DHT about 10% of those of testosterone, and approximately 0.3% of testosterone is converted into estradiol by aromatase.[3][169][175][176] 5α-Reductase is highly expressed in the male reproductive organs (including the prostate gland, seminal vesicles, and epididymides),[177] skin, hair follicles, and brain[178] and aromatase is highly expressed in adipose tissue, bone, and the brain.[179][180] As much as 90% of testosterone is converted into 5α-DHT in so-called androgenic tissues with high 5α-reductase expression,[170] and due to the several-fold greater potency of 5α-DHT as an AR agonist relative to testosterone,[181] it has been estimated that the effects of testosterone are potentiated 2- to 3-fold in such tissues.[182]


Total levels of testosterone in the body have been reported as 264 to 916 ng/dL (nanograms per deciliter) in non-obese European and American men age 19 to 39 years,[183] while mean testosterone levels in adult men have been reported as 630 ng/dL.[184] Although commonly used as a reference range,[185] some physicians have disputed the use of this range to determine hypogonadism.[186][187] Several professional medical groups have recommended that 350 ng/dl generally be considered the minimum normal level,[188] which is consistent with previous findings.[189]Template:Medref inline Levels of testosterone in men decline with age.[183] In women, mean levels of total testosterone have been reported to be 32.6 ng/dL.[190][191] In women with hyperandrogenism, mean levels of total testosterone have been reported to be 62.1 ng/dL.[190][191]

Total testosterone levels in males throughout life
Life stage Tanner stage Age range Mean age Levels range Mean levels
Child Stage I <10 years <30 ng/dL 5.8 ng/dL
Puberty Stage II 10–14 years 12 years <167 ng/dL 40 ng/dL
Stage III 12–16 years 13–14 years 21–719 ng/dL 190 ng/dL
Stage IV 13–17 years 14–15 years 25–912 ng/dL 370 ng/dL
Stage V 13–17 years 15 years 110–975 ng/dL 550 ng/dL
Adult ≥18 years 250–1,100 ng/dL 630 ng/dL
Sources: [192][193][184][194][195]
Reference ranges for blood tests, showing adult male testosterone levels in light blue at center-left


Testosterone's bioavailable concentration is commonly determined using the Vermeulen calculation or more precisely using the modified Vermeulen method,[196][197] which considers the dimeric form of sex-hormone-binding-globulin.[198]

Both methods use chemical equilibrium to derive the concentration of bioavailable testosterone: in circulation, testosterone has two major binding partners, albumin (weakly bound) and sex-hormone-binding-globulin (strongly bound). These methods are described in detail in the accompanying figure.


Nobel Prize winner, Leopold Ruzicka of Ciba, a pharmaceutical industry giant that synthesized testosterone

A testicular action was linked to circulating blood fractions – now understood to be a family of androgenic hormones – in the early work on castration and testicular transplantation in fowl by Arnold Adolph Berthold (1803–1861).[199] Research on the action of testosterone received a brief boost in 1889, when the Harvard professor Charles-Édouard Brown-Séquard (1817–1894), then in Paris, self-injected subcutaneously a "rejuvenating elixir" consisting of an extract of dog and guinea pig testicle. He reported in The Lancet that his vigor and feeling of well-being were markedly restored but the effects were transient,[200] and Brown-Séquard's hopes for the compound were dashed. Suffering the ridicule of his colleagues, he abandoned his work on the mechanisms and effects of androgens in human beings.

In 1927, the University of Chicago's Professor of Physiologic Chemistry, Fred C. Koch, established easy access to a large source of bovine testicles – the Chicago stockyards – and recruited students willing to endure the tedious work of extracting their isolates. In that year, Koch and his student, Lemuel McGee, derived 20 mg of a substance from a supply of 40 pounds of bovine testicles that, when administered to castrated roosters, pigs and rats, re-masculinized them.[201] The group of Ernst Laqueur at the University of Amsterdam purified testosterone from bovine testicles in a similar manner in 1934, but the isolation of the hormone from animal tissues in amounts permitting serious study in humans was not feasible until three European pharmaceutical giants – Schering (Berlin, Germany), Organon (Oss, Netherlands) and Ciba (Basel, Switzerland) – began full-scale steroid research and development programs in the 1930s.

The Organon group in the Netherlands were the first to isolate the hormone, identified in a May 1935 paper "On Crystalline Male Hormone from Testicles (Testosterone)".[202] They named the hormone testosterone, from the stems of testicle and sterol, and the suffix of ketone. The structure was worked out by Schering's Adolf Butenandt, at the Chemisches Institut of Technical University in Gdańsk.[203][204]

The chemical synthesis of testosterone from cholesterol was achieved in August that year by Butenandt and Hanisch.[205] Only a week later, the Ciba group in Zurich, Leopold Ruzicka (1887–1976) and A. Wettstein, published their synthesis of testosterone.[206] These independent partial syntheses of testosterone from a cholesterol base earned both Butenandt and Ruzicka the joint 1939 Nobel Prize in Chemistry.[204][207] Testosterone was identified as 17β-hydroxyandrost-4-en-3-one (C19H28O2), a solid polycyclic alcohol with a hydroxyl group at the 17th carbon atom. This also made it obvious that additional modifications on the synthesized testosterone could be made, i.e., esterification and alkylation.

The partial synthesis in the 1930s of abundant, potent testosterone esters permitted the characterization of the hormone's effects, so that Kochakian and Murlin (1936) were able to show that testosterone raised nitrogen retention (a mechanism central to anabolism) in the dog, after which Allan Kenyon's group[208] was able to demonstrate both anabolic and androgenic effects of testosterone propionate in eunuchoidal men, boys, and women. The period of the early 1930s to the 1950s has been called "The Golden Age of Steroid Chemistry",[209] and work during this period progressed quickly.[210]

Other species

Testosterone is observed in most vertebrates. Testosterone and the classical nuclear androgen receptor first appeared in gnathostomes (jawed vertebrates).[211] Agnathans (jawless vertebrates) such as lampreys do not produce testosterone but instead use androstenedione as a male sex hormone.[212] Fish make a slightly different form called 11-ketotestosterone.[213] Its counterpart in insects is ecdysone.[214] The presence of these ubiquitous steroids in a wide range of animals suggest that sex hormones have an ancient evolutionary history.[215]

See also


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Williams Textbook of Endocrinology. Elsevier Health Sciences. 30 November 2015. pp. 711–. ISBN 978-0-323-29738-7. 
  2. "Understanding the risks of performance-enhancing drugs" (in en). 
  3. 3.0 3.1 3.2 "Biological actions of androgens". Endocrine Reviews 8 (1): 1–28. Feb 1987. doi:10.1210/edrv-8-1-1. PMID 3549275. 
  4. "The benefits and risks of testosterone replacement therapy: a review". Therapeutics and Clinical Risk Management 5 (3): 427–48. Jun 2009. doi:10.2147/tcrm.s3025. PMID 19707253. 
  5. "Testosterone, bone and osteoporosis". Advances in the Management of Testosterone Deficiency. Frontiers of Hormone Research. 37. 2009. pp. 123–32. doi:10.1159/000176049. ISBN 978-3-8055-8622-1. 
  6. 6.0 6.1 "Chapter 2: Testosterone: Biosynthesis, transport, metabolism and (non-genomic) actions". Testosterone: Action, Deficiency, Substitution (4th ed.). Cambridge: Cambridge University Press. 2012. pp. 15–32. ISBN 978-1-107-01290-5. 
  7. "Serum testosterone in women as measured by an automated immunoassay and a RIA". Clinical Chemistry 50 (3): 678; author reply 678–9. Mar 2004. doi:10.1373/clinchem.2003.027565. PMID 14981046. 
  8. "Mean plasma concentration, metabolic clearance and basal plasma production rates of testosterone in normal young men and women using a constant infusion procedure: effect of time of day and plasma concentration on the metabolic clearance rate of testosterone". The Journal of Clinical Endocrinology & Metabolism 27 (5): 686–94. May 1967. doi:10.1210/jcem-27-5-686. PMID 6025472. 
  9. "Plasma production rates of testosterone in normal adult men and women and in patients with the syndrome of feminizing testes". The Journal of Clinical Endocrinology & Metabolism 25 (11): 1441–50. Nov 1965. doi:10.1210/jcem-25-11-1441. PMID 5843701. 
  10. Heroes, rogues, and lovers: testosterone and behavior. New York: McGraw-Hill. 2000. ISBN 978-0-07-135739-5. 
  11. 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 "Testosterone". American Society of Health-System Pharmacists. December 4, 2015. 
  12. (in en) Testosterone and Aging: Clinical Research Directions (Report). National Academies Press (US). 2004. 
  13. "What is Prohibited" (in en). 
  14. "Androgens and the control of skeletal muscle protein synthesis". Annals of Medicine 32 (3): 181–6. 2000. doi:10.3109/07853890008998825. PMID 10821325. 
  15. Gharahdaghi, N; Phillips, BE; Szewczyk, NJ; Smith, K; Wilkinson, DJ; Atherton, PJ (2020). "Links Between Testosterone, Oestrogen, and the Growth Hormone/Insulin-Like Growth Factor Axis and Resistance Exercise Muscle Adaptations.". Frontiers in Physiology 11: 621226. doi:10.3389/fphys.2020.621226. PMID 33519525. 
  16. Gharahdaghi, N; Rudrappa, S; Brook, MS; Farrash, W; Idris, I; Aziz, MHA; Kadi, F; Papaioannou, K et al. (April 2022). "Pharmacological hypogonadism impairs molecular transducers of exercise-induced muscle growth in humans.". Journal of Cachexia, Sarcopenia and Muscle 13 (2): 1134–1150. doi:10.1002/jcsm.12843. PMID 35233984. 
  17. Gharahdaghi, N; Rudrappa, S; Brook, MS; Idris, I; Crossland, H; Hamrock, C; Abdul Aziz, MH; Kadi, F et al. (December 2019). "Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men.". Journal of Cachexia, Sarcopenia and Muscle 10 (6): 1276–1294. doi:10.1002/jcsm.12472. PMID 31568675. 
  18. "Androgen Physiology, Pharmacology and Abuse". Endotext [Internet]., Inc. January 2013. 
  19. Sfetcu, Nicolae (2014-05-02) (in en). Health & Drugs: Disease, Prescription & Medication. Nicolae Sfetcu. 
  20. 20.0 20.1 "Sexual differentiation of the human brain in relation to gender identity and sexual orientation". Functional Neurology 24 (1): 17–28. 2009. PMID 19403051. 
  21. "Regulation of anti-Müllerian hormone (AMH) in males and the associations of serum AMH with the disorders of male fertility". Asian Journal of Andrology 21 (2): 109–114. 2019. doi:10.4103/aja.aja_83_18. PMID 30381580. 
  22. "Beyond Pink and Blue: The Complexity of Early Androgen Effects on Gender Development". Child Development Perspectives 12 (1): 58–64. March 2018. doi:10.1111/cdep.12261. PMID 29736184. 
  23. "Androgen and psychosexual development: core gender identity, sexual orientation and recalled childhood gender role behavior in women and men with congenital adrenal hyperplasia (CAH)". Journal of Sex Research 41 (1): 75–81. February 2004. doi:10.1080/00224490409552215. PMID 15216426. 
  24. "Evidence of testicular activity in early infancy". The Journal of Clinical Endocrinology & Metabolism 37 (1): 148–51. July 1973. doi:10.1210/jcem-37-1-148. PMID 4715291. 
  25. "The neonatal testosterone surge: a comparative study". Archives Internationales de Physiologie, de Biochimie et de Biophysique 100 (2): 127–31. 1992. doi:10.3109/13813459209035274. PMID 1379488. 
  26. "Neonatal stimulation of 5-HT(2) receptors reduces androgen receptor expression in the rat anteroventral periventricular nucleus and sexually dimorphic preoptic area". The European Journal of Neuroscience 27 (9): 2473–80. May 2008. doi:10.1111/j.1460-9568.2008.06216.x. PMID 18445234. 
  27. "Reproductive behaviors". Biological psychology. Belmont, Calif: Wadsworth, Cengage Learning. 2009. p. 321. ISBN 978-0-495-60300-9. 
  28. 28.0 28.1 "Puberty-timing is everything!". Journal of Pediatric Nursing 20 (2): 75–82. 2005. doi:10.1016/j.pedn.2004.12.011. PMID 15815567. 
  29. Ganong's Review of Medical Physiology (24 ed.). TATA McGRAW Hill. 2012. pp. 423–25. ISBN 978-1-25-902753-6. 
  30. "Cellular and molecular mechanisms of bone remodeling". The Journal of Biological Chemistry 285 (33): 25103–8. 2010. doi:10.1074/jbc.R109.041087. PMID 20501658. 
  31. "The social endocrinology of dominance: basal testosterone predicts cortisol changes and behavior following victory and defeat". Journal of Personality and Social Psychology 94 (6): 1078–1093. Jun 2008. doi:10.1037/0022-3514.94.6.1078. PMID 18505319. 
  32. "Castration reduces platelet thromboxane A2 receptor density and aggregability". QJM 98 (5): 349–356. May 2005. doi:10.1093/qjmed/hci054. PMID 15820970. 
  33. "Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses". Circulation 91 (11): 2742–2747. Jun 1995. doi:10.1161/01.CIR.91.11.2742. PMID 7758179. 
  34. "A validated age-related normative model for male total testosterone shows increasing variance but no decline after age 40 years". PLOS ONE 9 (10): e109346. October 8, 2014. doi:10.1371/journal.pone.0109346. PMID 25295520. Bibcode2014PLoSO...9j9346K. 
  35. "Testosterone and prostate safety". Advances in the Management of Testosterone Deficiency. Frontiers of Hormone Research. 37. 2009. pp. 197–203. doi:10.1159/000176054. ISBN 978-3-8055-8622-1. 
  36. "Androgen replacement in men undergoing treatment for prostate cancer". The Journal of Sexual Medicine 5 (9): 2202–08. Sep 2008. doi:10.1111/j.1743-6109.2008.00925.x. PMID 18638000. 
  37. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth". European Urology 55 (2): 310–20. Feb 2009. doi:10.1016/j.eururo.2008.09.024. PMID 18838208. 
  38. "Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials". Mayo Clinic Proceedings 82 (1): 29–39. Jan 2007. doi:10.4065/82.1.29. PMID 17285783. 
  39. "The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process". Atherosclerosis 207 (2): 318–27. Dec 2009. doi:10.1016/j.atherosclerosis.2009.04.016. PMID 19464009. 
  40. "Testosterone for the aging male; current evidence and recommended practice". Clinical Interventions in Aging 3 (1): 25–44. 2008. doi:10.2147/CIA.S190. PMID 18488876. 
  41. "Menstrual cycle irregularities are associated with testosterone levels in healthy premenopausal women". American Journal of Human Biology 18 (6): 841–44. 2006. doi:10.1002/ajhb.20555. PMID 17039468. 
  42. "Studies on the relationship between plasma testosterone levels and human sexual activity". The Journal of Endocrinology 52 (1): 51–8. Jan 1972. doi:10.1677/joe.0.0520051. PMID 5061159. 
  43. "Are gonadal steroids linked with orgasm perceptions and sexual assertiveness in women and men?". Hormones and Behavior 56 (2): 206–13. August 2009. doi:10.1016/j.yhbeh.2009.04.007. PMID 19409392. 
  44. "Cardiovascular and endocrine alterations after masturbation-induced orgasm in women". Psychosomatic Medicine 61 (3): 280–89. 1999. doi:10.1097/00006842-199905000-00005. PMID 10367606. 
  45. "Endocrine effects of masturbation in men". The Journal of Endocrinology 70 (3): 439–44. Sep 1976. doi:10.1677/joe.0.0700439. PMID 135817. 
  46. "Comparing the relative amount of testosterone required to restore sexual arousal, motivation, and performance in male rats". Hormones and Behavior 59 (5): 666–73. May 2011. doi:10.1016/j.yhbeh.2010.09.009. PMID 20920505. 
  47. "Sexually stimulated testosterone release in male mice (Mus musculus): roles of genotype and sexual arousal". Hormones and Behavior 50 (3): 424–31. Sep 2006. doi:10.1016/j.yhbeh.2006.05.004. PMID 16828762. 
  48. 48.0 48.1 "Sex and context: hormones and primate sexual motivation". Hormones and Behavior 40 (2): 339–57. Sep 2001. doi:10.1006/hbeh.2001.1696. PMID 11534996. 
  49. "Role of testosterone secretion and penile reflexes in sexual behavior and sperm competition in male rats: a theoretical contribution". Physiology & Behavior 31 (6): 823–27. Dec 1983. doi:10.1016/0031-9384(83)90279-2. PMID 6665072. 
  50. "Orgasmic frequency and plasma testosterone levels in normal human males". Archives of Sexual Behavior 5 (2): 125–32. Mar 1976. doi:10.1007/BF01541869. PMID 1275688. 
  51. "Behavioral and hormonal responses of men to brief interactions with women". Evolution and Human Behavior 24 (6): 365–75. 2003. doi:10.1016/S1090-5138(03)00053-9. 
  52. "Psychosexual stimulation and plasma testosterone in man". Archives of Sexual Behavior 3 (6): 577–84. Nov 1974. doi:10.1007/BF01541140. PMID 4429441. 
  53. "Changes in saliva testosterone after psychological stimulation in men". Psychoneuroendocrinology 10 (1): 77–81. 1985. doi:10.1016/0306-4530(85)90041-1. PMID 4001279. 
  54. "Endocrine, psychological and genital response to sexual arousal in men". Psychoneuroendocrinology 12 (2): 149–58. 1987. doi:10.1016/0306-4530(87)90045-X. PMID 3602262. 
  55. "Scent of a woman: men's testosterone responses to olfactory ovulation cues". Psychological Science 21 (2): 276–83. Feb 2010. doi:10.1177/0956797609357733. PMID 20424057. 
  56. "Adaptations to Ovulation: Implications for Sexual and Social Behavior". Current Directions in Psychological Science 14 (6): 312–16. 2005. doi:10.1111/j.0963-7214.2005.00388.x. 
  57. "Role of androgens in female genital sexual arousal: receptor expression, structure, and function". Fertility and Sterility 77 (Suppl 4): S11–8. Apr 2002. doi:10.1016/s0015-0282(02)02978-3. PMID 12007897. 
  58. "Associations between testosterone secretion and sexual activity in women". Hormones and Behavior 51 (4): 477–82. Apr 2007. doi:10.1016/j.yhbeh.2007.01.003. PMID 17320881. 
  59. "Time course of effects of testosterone administration on sexual arousal in women". Archives of General Psychiatry 57 (2): 149–53; discussion 155–6. Feb 2000. doi:10.1001/archpsyc.57.2.149. PMID 10665617. 
  60. "Sexy thoughts: effects of sexual cognitions on testosterone, cortisol, and arousal in women". Hormones and Behavior 59 (5): 754–64. May 2011. doi:10.1016/j.yhbeh.2010.12.005. PMID 21185838. 
  61. 61.0 61.1 "Testosterone therapy in women: a review". International Journal of Impotence Research 17 (5): 399–408. 2005. doi:10.1038/sj.ijir.3901334. PMID 15889125. 
  62. 62.0 62.1 "Romantic Love and Reproductive Hormones in Women". Int J Environ Res Public Health 16 (21): 4224. October 2019. doi:10.3390/ijerph16214224. PMID 31683520. 
  63. 63.0 63.1 63.2 "Hormonal changes when falling in love". Psychoneuroendocrinology 29 (7): 931–36. August 2004. doi:10.1016/j.psyneuen.2003.08.006. PMID 15177709. 
  64. 64.0 64.1 "Relationship status and testosterone in North American heterosexual and non-heterosexual men and women: cross-sectional and longitudinal data". Psychoneuroendocrinology 31 (6): 715–23. July 2006. doi:10.1016/j.psyneuen.2006.01.008. PMID 16621328. 
  65. 65.0 65.1 65.2 "Testosterone and Men's Marriages". Social Forces 72 (2): 463–77. 1993. doi:10.1093/sf/72.2.463. 
  66. "Marriage, Divorce, and Male Testosterone". Social Forces 77 (1): 315–30. 1998. doi:10.1093/sf/77.1.315. 
  67. "Human male pair bonding and testosterone". Human Nature 15 (2): 119–31. Jun 2004. doi:10.1007/s12110-004-1016-6. PMID 26190409. 
  68. "Social variables predict between-subject but not day-to-day variation in the testosterone of US men". Psychoneuroendocrinology 29 (9): 1153–62. Oct 2004. doi:10.1016/j.psyneuen.2004.01.008. PMID 15219639. 
  69. "Testosterone levels in women and men who are single, in long-distance relationships, or same-city relationships". Hormones and Behavior 51 (2): 286–91. Feb 2007. doi:10.1016/j.yhbeh.2006.11.005. PMID 17196592. 
  70. "Male Life History, Reproductive Effort, and the Evolution of the Genus Homo". Current Anthropology 53 (S6): S424–S435. December 2012. doi:10.1086/667538. 
  71. "When mothers need others: The impact of hominin life history evolution on cooperative breeding". Journal of Human Evolution 84: 16–24. July 2015. doi:10.1016/j.jhevol.2015.01.009. PMID 25843884. 
  72. "Applying socioendocrinology to evolutionary models: fatherhood and physiology". Evolutionary Anthropology 23 (4): 146–60. 2014-07-08. doi:10.1002/evan.21412. PMID 25116846. 
  73. "Parenting Skills Influenced by Testosterone Levels, Empathy". 2015-10-30. 
  74. 74.0 74.1 "Gender differences in financial risk aversion and career choices are affected by testosterone". Proceedings of the National Academy of Sciences of the United States of America 106 (36): 15268–73. September 2009. doi:10.1073/pnas.0907352106. PMID 19706398. Bibcode2009PNAS..10615268S. 
  75. "Testosterone and financial risk preferences". Evolution and Human Behavior 29 (6): 384–90. November 2008. doi:10.1016/j.evolhumbehav.2008.07.001. 
  76. 76.0 76.1 Handbook of crime correlates. San Diego: Academic Press. 2009. pp. 208–10. ISBN 978-0-12-373612-3. 
  77. "Testosterone facilitates aggression by modulating vasopressin receptors in the hypothalamus". Physiology & Behavior 60 (1): 25–9. July 1996. doi:10.1016/0031-9384(95)02246-5. PMID 8804638. 
  78. 78.0 78.1 78.2 78.3 78.4 "Testosterone and human aggression: an evaluation of the challenge hypothesis". Neuroscience and Biobehavioral Reviews 30 (3): 319–345. 2006. doi:10.1016/j.neubiorev.2004.12.007. PMID 16483890. 
  79. 79.0 79.1 "The evolutionary neuroandrogenic theory of criminal behavior expanded". Aggression and Violent Behavior 24: 61–74. 2015. doi:10.1016/j.avb.2015.05.002. 
  80. "Fetal Testosterone and Criminality: Test of Evolutionary Neuroandrogenic Theory". Criminology 53 (1): 54–73. 2015. doi:10.1111/1745-9125.12056. 
  81. "The second-to-fourth digit ratio correlates with aggressive behavior in professional soccer players". Molecular Medicine Reports 7 (6): 1733–1738. Jun 2013. doi:10.3892/mmr.2013.1426. PMID 23588344. 
  82. "Finger length ratio (2D:4D) correlates with physical aggression in men but not in women". Biological Psychology 68 (3): 215–222. Mar 2005. doi:10.1016/j.biopsycho.2004.05.001. PMID 15620791. 
    Lay summary: "Finger Length Predicts Aggression in Men". 2 March 2005. 
  83. "Digit length ratios predict reactive aggression in women, but not in men". Hormones and Behavior 46 (5): 558–564. Dec 2004. doi:10.1016/j.yhbeh.2004.06.004. PMID 15555497. 
  84. "Association between a marker for prenatal testosterone exposure and externalizing behavior problems in children". Development and Psychopathology 24 (3): 771–782. August 2012. doi:10.1017/S0954579412000363. PMID 22781854. 
  85. "Digit ratio (2D:4D), aggression, and dominance in the Hadza and the Datoga of Tanzania". American Journal of Human Biology 27 (5): 620–627. 2015-10-01. doi:10.1002/ajhb.22718. PMID 25824265. 
  86. "Second to fourth digit ratio confirms aggressive tendencies in patients with boxers fractures". Injury 44 (11): 1636–1639. Nov 2013. doi:10.1016/j.injury.2013.07.018. PMID 23972912. 
  87. "Social neuroendocrinology of human aggression: examining the role of competition-induced testosterone dynamics". Neuroscience 286: 171–186. Feb 2015. doi:10.1016/j.neuroscience.2014.11.029. PMID 25463514. 
  88. "Guns, testosterone, and aggression: an experimental test of a mediational hypothesis". Psychological Science 17 (7): 568–571. July 2006. doi:10.1111/j.1467-9280.2006.01745.x. PMID 16866740. 
  89. "The Interacting Roles of Testosterone and Challenges to Status in Human Male Aggression". Aggression and Violent Behavior 14 (5): 330–335. 2009. doi:10.1016/j.avb.2009.04.006. 
  90. "Testosterone reactivity and identification with a perpetrator or a victim in a story are associated with attraction to violence-related cues". International Journal of Law and Psychiatry 37 (3): 304–312. 2014-05-01. doi:10.1016/j.ijlp.2013.11.016. PMID 24367977. 
  91. "A testosterone-related structural brain phenotype predicts aggressive behavior from childhood to adulthood". Psychoneuroendocrinology 63: 109–118. Jan 2016. doi:10.1016/j.psyneuen.2015.09.021. PMID 26431805. 
  92. "Prejudice and truth about the effect of testosterone on human bargaining behaviour". Nature 463 (7279): 356–59. 2010. doi:10.1038/nature08711. PMID 19997098. Bibcode2010Natur.463..356E. 
  93. "New evidence on testosterone and cooperation". Nature 485 (7399): E4–5; discussion E5–6. May 2012. doi:10.1038/nature11136. PMID 22622587. Bibcode2012Natur.485E...4V. 
  94. "Eisenegger et al. reply". Nature 485 (7399): E5–E6. 2012. doi:10.1038/nature11137. Bibcode2012Natur.485E...5E. 
  95. "Testosterone administration decreases generosity in the ultimatum game". PLOS ONE 4 (12): e8330. 2009-01-01. doi:10.1371/journal.pone.0008330. PMID 20016825. Bibcode2009PLoSO...4.8330Z. 
  96. "Anabolic androgenic steroids and aggression: studies using animal models". Annals of the New York Academy of Sciences 1036: 399–415. Dec 2004. doi:10.1196/annals.1330.024. PMID 15817752. Bibcode2004NYASA1036..399M. 
  97. "Testosterone, 5 alpha-dihydrotestosterone and cortisol in men with and without alcohol-related aggression". Journal of Studies on Alcohol 63 (5): 518–26. Sep 2002. doi:10.15288/jsa.2002.63.518. PMID 12380846. 
  98. Goldman D, Lappalainen J, Ozaki N. Direct analysis of candidate genes in impulsive disorders. In: Bock G, Goode J, eds. Genetics of Criminal and Antisocial Behaviour. Ciba Foundation Symposium 194. Chichester: John Wiley & Sons; 1996.
  99. "Neurotransmitter correlates of impulsive aggression in humans. In: Ferris C, Grisso T, eds. Understanding Aggressive Behaviour inn Children". Annals of the New York Academy of Sciences 794 (1): 82–89. 1996. doi:10.1111/j.1749-6632.1996.tb32511.x. PMID 8853594. Bibcode1996NYASA.794...82C. 
  100. "Estrogen or testosterone increases self-reported aggressive behaviors in hypogonadal adolescents". The Journal of Clinical Endocrinology & Metabolism 82 (8): 2433–38. 1997. doi:10.1210/jcem.82.8.4165. PMID 9253313. 
  101. "Novel mechanisms for neuroendocrine regulation of aggression". Frontiers in Neuroendocrinology 29 (4): 476–89. Oct 2008. doi:10.1016/j.yfrne.2007.12.003. PMID 18280561. 
  102. "Acute and chronic effects of an aromatase inhibitor on territorial aggression in breeding and nonbreeding male song sparrows". Journal of Comparative Physiology A 186 (7–8): 759–69. 2000. doi:10.1007/s003590000129. PMID 11016791. 
  103. "Physical provocation potentiates aggression in male rats receiving anabolic androgenic steroids". Hormones and Behavior 41 (1): 101–10. Feb 2002. doi:10.1006/hbeh.2001.1742. PMID 11863388. 
  104. "Doubled-Edged Swords in the Biology of Conflict". Frontiers in Psychology 9: 2625. 2018. doi:10.3389/fpsyg.2018.02625. PMID 30619017. 
  105. The trouble with testosterone.. New York: Simon and Schuster. 1998. pp. 153–55. ISBN 978-0-684-83891-5. 
  106. "The role of testosterone in social interaction". Trends in Cognitive Sciences 15 (6): 263–71. June 2011. doi:10.1016/j.tics.2011.04.008. PMID 21616702. 
  107. "Androgens, androgen receptors, and male gender role behavior". Hormones and Behavior 40 (2): 358–66. Sep 2001. doi:10.1006/hbeh.2001.1684. PMID 11534997. 
  108. "Evolving knowledge of sex differences in brain structure, function, and chemistry". Biological Psychiatry 62 (8): 847–55. Oct 2007. doi:10.1016/j.biopsych.2007.03.001. PMID 17544382. 
  109. "Marked loss of myelinated nerve fibers in the human brain with age". The Journal of Comparative Neurology 462 (2): 144–52. July 2003. doi:10.1002/cne.10714. PMID 12794739. 
  110. "The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men". The New England Journal of Medicine 335 (1): 1–7. July 1996. doi:10.1056/NEJM199607043350101. PMID 8637535. 
  111. "Testosterone Affects Some Women's Career Choices". NPR. August 28, 2009. 
  112. "Androgens, aging, and Alzheimer's disease". Endocrine 29 (2): 233–41. Apr 2006. doi:10.1385/ENDO:29:2:233. PMID 16785599. 
  113. "Age-related testosterone depletion and the development of Alzheimer disease". JAMA 292 (12): 1431–32. Sep 2004. doi:10.1001/jama.292.12.1431-b. PMID 15383512. 
  114. "Low free testosterone is an independent risk factor for Alzheimer's disease". Experimental Gerontology 39 (11–12): 1633–39. 2004. doi:10.1016/j.exger.2004.06.019. PMID 15582279. 
  115. "Free testosterone and risk for Alzheimer disease in older men". Neurology 62 (2): 188–93. Jan 2004. doi:10.1212/WNL.62.2.188. PMID 14745052. 
  116. "A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference". Psychoneuroendocrinology 21 (3): 323–37. Apr 1996. doi:10.1016/0306-4530(95)00051-8. PMID 8817730. 
  117. 117.0 117.1 117.2 117.3 "The Anti-Inflammatory Effects of Testosterone". Journal of the Endocrine Society 3 (1): 91–107. January 2019. doi:10.1210/js.2018-00186. PMID 30582096. 
  118. "The effect of testosterone on thyroid autoimmunity in euthyroid men with Hashimoto's thyroiditis and low testosterone levels". Journal of Clinical Pharmacy and Therapeutics 44 (5): 742–749. October 2019. doi:10.1111/jcpt.12987. PMID 31183891. 
  119. "List of Gender Dysphoria Medications (6 Compared)" (in en). 
  120. "Androgen replacement therapy in the aging male". Reviews in Urology 5 (4): 216–226. 2003. PMID 16985841. 
  121. "Testosterone Products: Drug Safety Communication – FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke". FDA. 3 March 2015. 
  122. "19th WHO Model List of Essential Medicines (April 2015)". WHO. April 2015. 
  123. "Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians". Annals of Internal Medicine 172 (2): 126–133. January 2020. doi:10.7326/M19-0882. PMID 31905405. 
  124. "New Guideline for Testosterone Treatment in Men With 'Low T'". 7 January 2020. 
  125. "The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status". JBMR Plus 5 (1): e10418. January 2021. doi:10.1002/jbm4.10418. PMID 33553985. 
  126. "Molecular mechanism of androgen action". Trends in Endocrinology and Metabolism 9 (8): 317–24. Oct 1998. doi:10.1016/S1043-2760(98)00081-2. PMID 18406296. 
  127. "Complexities of androgen action". Journal of the American Academy of Dermatology 45 (3 Suppl): S87–94. Sep 2001. doi:10.1067/mjd.2001.117429. PMID 11511858. 
  128. "Molecular cell biology of androgen receptor signalling". Int. J. Biochem. Cell Biol. 42 (6): 813–27. 2010. doi:10.1016/j.biocel.2009.11.013. PMID 19931639. 
  129. "G protein-coupled receptors: extranuclear mediators for the non-genomic actions of steroids". Int J Mol Sci 15 (9): 15412–25. 2014. doi:10.3390/ijms150915412. PMID 25257522. 
  130. "Targeting membrane androgen receptors in tumors". Expert Opin. Ther. Targets 17 (8): 951–63. 2013. doi:10.1517/14728222.2013.806491. PMID 23746222. 
  131. "Inhibition of androgen receptor binding by natural and synthetic steroids in cultured human genital skin fibroblasts". Klinische Wochenschrift 64 (16): 732–37. August 1986. doi:10.1007/BF01734339. PMID 3762019. 
  132. Estrogen signaling in the hypothalamus. Vitamins & Hormones. 71. 2005-01-01. pp. 123–45. doi:10.1016/S0083-6729(05)71005-0. ISBN 9780127098715. 
  133. "Estradiol and the developing brain". Physiological Reviews 88 (1): 91–124. 2008. doi:10.1152/physrev.00010.2007. PMID 18195084. 
  134. "Dissociating behavioral, autonomic, and neuroendocrine effects of androgen steroids in animal models". Psychiatric Disorders. 829. 2012. 397–431. doi:10.1007/978-1-61779-458-2_26. ISBN 978-1-61779-457-5. 
  135. 135.0 135.1 "Novel mechanisms for DHEA action". J. Mol. Endocrinol. 56 (3): R139–55. 2016. doi:10.1530/JME-16-0013. PMID 26908835. 
  136. 136.0 136.1 "Neurosteroid dehydroepiandrosterone interacts with nerve growth factor (NGF) receptors, preventing neuronal apoptosis". PLOS Biol. 9 (4): e1001051. 2011. doi:10.1371/journal.pbio.1001051. PMID 21541365. 
  137. 137.0 137.1 "Neurosteroids and microneurotrophins signal through NGF receptors to induce prosurvival signaling in neuronal cells". Sci Signal 5 (246): pt8. 2012. doi:10.1126/scisignal.2003387. PMID 23074265. 
  138. "Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders". Sigma Receptors: Their Role in Disease and as Therapeutic Targets. 964. 2017. 153–161. doi:10.1007/978-3-319-50174-1_11. ISBN 978-3-319-50172-7. 
  139. Sex and Gender Differences in Pharmacology. Springer Science & Business Media. 2 October 2012. pp. 245–. ISBN 978-3-642-30725-6. 
  140. "Diagram of the pathways of human steroidogenesis". WikiJournal of Medicine 1 (1). 2014. doi:10.15347/wjm/2014.005. 
  141. "Genes involved in androgen biosynthesis and the male phenotype". Hormone Research 38 (5–6): 217–21. 1992. doi:10.1159/000182546. PMID 1307739. 
  142. "Expression of bovine 17 alpha-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells". Science 234 (4781): 1258–61. Dec 1986. doi:10.1126/science.3535074. PMID 3535074. Bibcode1986Sci...234.1258Z. 
  143. "Androgen action on human skin – from basic research to clinical significance". Experimental Dermatology 13 (Suppl 4): 5–10. 2004. doi:10.1111/j.1600-0625.2004.00255.x. PMID 15507105. 
  144. "Androgens". Clinics in Endocrinology and Metabolism 4 (3): 503–20. Nov 1975. doi:10.1016/S0300-595X(75)80045-4. PMID 58744. 
  145. "Structure, function, and regulation of steroidogenic enzymes in the Leydig cell". Leydig Cell. Vienna [Il]: Cache River Press. 1996. pp. 260–85. ISBN 978-0-9627422-7-9. 
  146. "Developments in the control of testicular function". Baillière's Clinical Endocrinology and Metabolism 6 (2): 451–83. Apr 1992. doi:10.1016/S0950-351X(05)80158-2. PMID 1377467. 
  147. "Introduction". Testosterone and Aging: Clinical Research Directions.. National Academies Press (US). January 1, 2004. doi:10.17226/10852. ISBN 978-0-309-09063-6. 
  148. "Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment". Asian Journal of Andrology 16 (2): 192–202. 2014. doi:10.4103/1008-682X.122336. PMID 24407185. 
  149. "Andropause--lessons from the European Male Ageing Study". Annales d'Endocrinologie 75 (2): 128–31. 2014. doi:10.1016/j.ando.2014.03.005. PMID 24793989. 
  150. "Testosterone physiology in resistance exercise and training: the up-stream regulatory elements". Sports Medicine 40 (12): 1037–53. 2010. doi:10.2165/11536910-000000000-00000. PMID 21058750. 
  151. "Androgen receptors and testosterone in men—effects of protein ingestion, resistance exercise and fiber type". The Journal of Steroid Biochemistry and Molecular Biology 110 (1–2): 130–37. May 2008. doi:10.1016/j.jsbmb.2008.03.030. PMID 18455389. 
  152. "Testosterone and endurance exercise: development of the "exercise-hypogonadal male condition"". Acta Physiologica Hungarica 92 (2): 121–37. 2005. doi:10.1556/APhysiol.92.2005.2.3. PMID 16268050. 
  153. "Regulation and perturbation of testicular functions by vitamin A". Reproduction 124 (2): 173–180. August 2002. doi:10.1530/rep.0.1240173. PMID 12141930. 
  154. "Effect of vitamin D supplementation on testosterone levels in men". Hormone and Metabolic Research 43 (3): 223–225. March 2011. doi:10.1055/s-0030-1269854. PMID 21154195. 
  155. "Zinc status and serum testosterone levels of healthy adults". Nutrition 12 (5): 344–348. May 1996. doi:10.1016/S0899-9007(96)80058-X. PMID 8875519. 
  156. "Serum testosterone and urinary excretion of steroid hormone metabolites after administration of a high-dose zinc supplement". European Journal of Clinical Nutrition 63 (1): 65–70. January 2009. doi:10.1038/sj.ejcn.1602899. PMID 17882141. 
  157. "Low-fat diets and testosterone in men: Systematic review and meta-analysis of intervention studies". The Journal of Steroid Biochemistry and Molecular Biology 210: 105878. June 2021. doi:10.1016/j.jsbmb.2021.105878. PMID 33741447. 
  158. "Low-carbohydrate diets and men's cortisol and testosterone: Systematic review and meta-analysis". Nutrition and Health 28 (4): 543–554. March 2022. doi:10.1177/02601060221083079. PMID 35254136. 
  159. "Does weight loss improve semen quality and reproductive hormones? Results from a cohort of severely obese men". Reproductive Health 8 (1): 24. 2011. doi:10.1186/1742-4755-8-24. PMID 21849026. 
  160. "The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis". Human Reproduction Update 16 (3): 293–311. 2010. doi:10.1093/humupd/dmp047. PMID 19889752. 
  161. "The effects of testosterone on sleep and sleep-disordered breathing in men: its bidirectional interaction with erectile function". Sleep Medicine Reviews 12 (5): 365–79. Oct 2008. doi:10.1016/j.smrv.2007.12.003. PMID 18519168. 
  162. "Implicit power motivation moderates men's testosterone responses to imagined and real dominance success". Hormones and Behavior 36 (3): 234–41. Dec 1999. doi:10.1006/hbeh.1999.1542. PMID 10603287. 
  163. "Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism". Phytotherapy Research 21 (5): 444–47. May 2007. doi:10.1002/ptr.2074. PMID 17310494. 
  164. "Spearmint induced hypothalamic oxidative stress and testicular anti-androgenicity in male rats - altered levels of gene expression, enzymes and hormones". Food and Chemical Toxicology 46 (12): 3563–70. Dec 2008. doi:10.1016/j.fct.2008.08.027. PMID 18804513. 
  165. "Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial". Phytotherapy Research 24 (2): 186–88. Feb 2010. doi:10.1002/ptr.2900. PMID 19585478. 
  166. "History of the endocrine effects of licorice". Experimental and Clinical Endocrinology & Diabetes 110 (6): 257–61. Sep 2002. doi:10.1055/s-2002-34587. PMID 12373628. 
  167. Testosterone: Action, Deficiency, Substitution. Cambridge University Press. 26 July 2012. pp. 61–. ISBN 978-1-107-01290-5. 
  168. "Non-sex hormone-binding globulin-bound testosterone as a marker for hyperandrogenism". The Journal of Clinical Endocrinology & Metabolism 61 (5): 873–6. November 1985. doi:10.1210/jcem-61-5-873. PMID 4044776. 
  169. 169.0 169.1 169.2 169.3 169.4 169.5 169.6 169.7 169.8 169.9 Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001. pp. 1116, 1119, 1183. ISBN 978-0-7817-1750-2. 
  170. 170.0 170.1 170.2 170.3 Brody's Human Pharmacology. Elsevier Health Sciences. 1 April 2009. pp. 468–469. ISBN 978-0-323-07575-6. 
  171. "New frontiers in androgen biosynthesis and metabolism". Curr Opin Endocrinol Diabetes Obes 17 (3): 233–9. 2010. doi:10.1097/MED.0b013e3283381a31. PMID 20186052. 
  172. Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. 6 December 2012. pp. 107–. ISBN 978-94-009-8195-9. 
  173. 173.0 173.1 173.2 173.3 173.4 Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism. CRC Press. 6 April 2016. pp. 242–. ISBN 978-1-4665-9788-4. 
  174. (in de) Steroidhormone: Biosynthese, Stoffwechsel, Wirkung. Springer-Verlag. 1977. p. 349. ISBN 978-0-387-08012-3. 
  175. "Role of 5 alpha-reductase in health and disease". Baillière's Clinical Endocrinology and Metabolism 8 (2): 405–31. Apr 1994. doi:10.1016/S0950-351X(05)80259-9. PMID 8092979. 
  176. "The essential role of the aromatase/p450arom". Seminars in Reproductive Medicine 20 (3): 277–84. August 2002. doi:10.1055/s-2002-35374. PMID 12428207. 
  177. Arthur's Veterinary Reproduction and Obstetrics. Elsevier Health Sciences UK. 23 April 2009. pp. 695–. ISBN 978-0-7020-3990-4. 
  178. Testosterone: Action, Deficiency, Substitution. Cambridge University Press. 1 April 2004. pp. 626–. ISBN 978-1-139-45221-2. 
  179. Estrogens, Estrogen Receptor and Breast Cancer. IOS Press. 2000. pp. 25–. ISBN 978-0-9673355-4-4. 
  180. Hormones. Academic Press. 30 July 2014. pp. 261–. ISBN 978-0-08-091906-5. 
  181. Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. 18 September 2011. pp. 656–. ISBN 978-1-61779-222-9. 
  182. "Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens". J. Steroid Biochem. Mol. Biol. 53 (1–6): 253–7. 1995. doi:10.1016/0960-0760(95)00056-6. PMID 7626464. 
  183. 183.0 183.1 "Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe". The Journal of Clinical Endocrinology and Metabolism 102 (4): 1161–1173. April 2017. doi:10.1210/jc.2016-2935. PMID 28324103. 
  184. 184.0 184.1 Pediatric Endocrinology E-Book. Elsevier Health Sciences. 10 April 2014. pp. 488–. ISBN 978-1-4557-5973-6. 
  185. "Testosterone, total". 
  186. "Andrology: Testosterone reference ranges and diagnosis of testosterone deficiency". Nature Reviews. Urology 14 (5): 263–264. May 2017. doi:10.1038/nrurol.2017.35. PMID 28266512. 
  187. "Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions". The Journal of Sexual Medicine 11 (7): 1636–1645. July 2014. doi:10.1111/jsm.12546. PMID 24797325. 
  188. "ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males". International Journal of Impotence Research 21 (1): 1–8. 16 October 208. doi:10.1038/ijir.2008.41. PMID 18923415. 
  189. "Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts". The Journal of Clinical Endocrinology and Metabolism 96 (8): 2430–2439. August 2011. doi:10.1210/jc.2010-3012. PMID 21697255. 
  190. 190.0 190.1 Evidence-Based Endocrinology. Lippincott Williams & Wilkins. 26 September 2012. pp. 217–. ISBN 978-1-4511-7146-4. 
  191. 191.0 191.1 "Utilization of commercial laboratory results in management of hyperandrogenism in women". Endocrine Practice 4 (1): 1–10. 1998. doi:10.4158/EP.4.1.1. PMID 15251757. 
  192. Berman's Pediatric Decision Making. Elsevier Health Sciences. 1 January 2011. pp. 160–. ISBN 978-0-323-05405-8. 
  193. Pediatric Endocrinology: A Clinical Handbook. Springer. 25 April 2016. pp. 191–. ISBN 978-3-319-18371-8. 
  194. Mosby's Diagnostic and Laboratory Test Reference – E-Book. Elsevier Health Sciences. 19 September 2014. pp. 879–. ISBN 978-0-323-22592-2. 
  195. The Harriet Lane Handbook E-Book. Elsevier Health Sciences. 1 May 2014. pp. 240–. ISBN 978-0-323-11246-8. 
  196. "Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms". Clinical Chemistry 52 (9): 1777–84. September 2006. doi:10.1373/clinchem.2005.063354. PMID 16793931. 
  197. "Impact of recent biochemical findings on the determination of free and bioavailable testosterone: evaluation and proposal for clinical use". LaboratoriumsMedizin 30 (6): 492–505. 1 January 2006. doi:10.1515/JLM.2006.050. 
  198. "RCSB PDB - 1D2S". Crystal Structure of the N-Terminal Laminin G-Like Domain of SHBG in Complex with Dihydrotestosterone. 
  199. "Transplantation der Hoden" (in de). Arch. Anat. Physiol. Wiss. 16: 42–46. 1849. 
  200. "The effects produced on man by subcutaneous injections of liquid obtained from the testicles of animals". Lancet 2 (3438): 105–107. 1889. doi:10.1016/S0140-6736(00)64118-1. 
  201. "The testicular hormone". J. Biol. Chem. 84 (2): 495–500. November 1929. doi:10.1016/S0021-9258(18)77008-7. 
  202. "Über krystallinisches mannliches Hormon aus Hoden (Testosteron) wirksamer als aus harn oder aus Cholesterin bereitetes Androsteron" (in de). Hoppe-Seyler's Z Physiol Chem 233 (5–6): 281–83. May 1935. doi:10.1515/bchm2.1935.233.5-6.281. 
  203. "Umwandlung des Dehydroandrosterons in Androstendiol und Testosterone; ein Weg zur Darstellung des Testosterons aus Cholestrin" (in de). Hoppe-Seyler's Z Physiol Chem 237 (2): 89–97. 1935. doi:10.1515/bchm2.1935.237.1-3.89. 
  204. 204.0 204.1 "A brief history of testosterone". The Journal of Urology 165 (2): 371–73. Feb 2001. doi:10.1097/00005392-200102000-00004. PMID 11176375. 
  205. "Uber die Umwandlung des Dehydroandrosterons in Androstenol-(17)-one-(3) (Testosterone); um Weg zur Darstellung des Testosterons auf Cholesterin (Vorlauf Mitteilung). [The conversion of dehydroandrosterone into androstenol-(17)-one-3 (testosterone); a method for the production of testosterone from cholesterol (preliminary communication)]" (in de). Chemische Berichte 68 (9): 1859–62. 1935. doi:10.1002/cber.19350680937. 
  206. "Uber die kristallinische Herstellung des Testikelhormons, Testosteron (Androsten-3-ol-17-ol) [The crystalline production of the testicle hormone, testosterone (Androsten-3-ol-17-ol)]" (in de). Helvetica Chimica Acta 18: 1264–75. 1935. doi:10.1002/hlca.193501801176. 
  207. "The history of synthetic testosterone". Scientific American 272 (2): 76–81. Feb 1995. doi:10.1038/scientificamerican0295-76. PMID 7817189. Bibcode1995SciAm.272b..76H. 
  208. "A comparative study of the metabolic effects of testosterone propionate in normal men and women and in eunuchoidism". Endocrinology 26 (1): 26–45. February 1940. doi:10.1210/Endo-26-1-26. 
  209. "The steroid story of Jenapharm: from the late 1940s to the early 1970s". Steroids 64 (7): 439–45. July 1999. doi:10.1016/S0039-128X(99)00003-3. PMID 10443899. 
  210. The Male Hormone. New York: Harcourt, Brace. 1945. 
  211. "Vertebrate sex steroid receptors: evolution, ligands, and neurodistribution". Annals of the New York Academy of Sciences 1163 (1): 154–68. 2009. doi:10.1111/j.1749-6632.2009.04460.x. PMID 19456336. Bibcode2009NYASA1163..154G. 
  212. "Sex steroids and their receptors in lampreys". Steroids 73 (1): 1–12. 2008. doi:10.1016/j.steroids.2007.08.011. PMID 17931674. 
  213. An introduction to behavioral endocrinology. Sunderland, Mass: Sinauer Associates. 2005. p. 143. ISBN 978-0-87893-617-5. 
  214. "Ecdysteroids: the overlooked sex steroids of insects? Males: the black box". Insect Science 13 (5): 325–338. October 2006. doi:10.1111/j.1744-7917.2006.00101.x. 
  215. "Estrogens in insects". Cellular and Molecular Life Sciences 40 (9): 942–44. September 1984. doi:10.1007/BF01946450. 

Further reading


| name = Androgens and antiandrogens
| title = Androgens and antiandrogens
| state = collapsed
| listclass = hlist
| groupstyle = text-align:center;
| group1 = Androgens
(incl. AAS)

| list1 =

  | group3 = Antigonadotropins
  | list3 =
  | group4 = Others
  | list4 =
| liststyle = background:#DDDDFF;
| list3 =
See also
Androgen receptor modulators
Estrogens and antiestrogens
Progestogens and antiprogestogens
List of androgens/anabolic steroids